Innovative Wearable and Open Platform for a Personalized Treatment of Stress

Información del proyecto

XANA

Identificador del acuerdo de subvención: 781703

DOI

10.3030/781703

Proyecto cerrado

Fecha de la firma de la CE 17 Julio 2017

Fecha de inicio 1 Agosto 2017

Fecha de finalización 30 Noviembre 2017

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

WALDEN MEDICAL NEURO DIGITAL THERAPIES, S.L.
Spain

Periodic Reporting for period 1 - XANA (Innovative Wearable and Open Platform for a Personalized Treatment of Stress)

Período documentado: 2017-08-01 hasta 2017-11-30

Resumen del contexto y de los objetivos generales del proyecto

Walden Medical® has been created aiming to design, develop and commercialize XANA product (device and platform): a personalized and non-invasive neurostimulation treatment for stress relief. Previous R&D project results, where three of the founders were involved, showed the potential and technical viability required for boosting the creation of the company.
The initial goal was to develop a non-invasive system to stimulate parasympathetic nervous system activity and thus maintain homeostasis, compensating for the excessive activation of the sympathetic nervous system due to the response to stressful stimuli.
After several anatomical and physiological studies, we designed an ergonomic and usable wearable neurostimulator operated from a software app for smartphone and capable of electrically stimulating the Auricular Brach of the Vagus Nerve.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Once the design was completed, we developed the prototype for a Minimum Viable Product (MVP) that consists of an auricular electrical neurostimulator connected by Bluetooth to our software app.
This development process served also to determine the functional properties and specifications for the optimization of the XANA MVP product. The improvements to get a more user-friendly, efficient and customized product (XANA BCAS) are:
Bilateral: one stimulator for each ear, to improve efficiency.
Customized: An scan of the user´s auditory canals will be used to build the anatomically customized stimulators.
Autonomous: the stimulators can operate without the smartphone.
SMART: implementation of both electrical and mechanical stimulation and music therapy.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Since stress affects over 40% of the worldwide population and is linked to over 70% of physical and mental disorders XANA will help to:
1. Solve a high prevalence problem associated to current lifestyle.
2. Prevent other conditions that can be triggered by stress (e.g. anxiety, depression).
3. Decrease the costs of absenteeism and reduce the enormous healthcare system costs, directly caused by stress and indirectly caused by stress-linked-conditions.
4. Reduce the abuse of medication (Benzodiazepines) that causes addiction among other serious side-effects.
5. Develop the mobile Health offer which is the main social trend regarding prevention, monitoring and treatment in the health sector.

xana.png

walden.png